Non-linear relationships between children age and pneumococcal vaccine coverage: Important implications for vaccine prevention strategies

Yanling Liu,Wenhui Li,Qian Dong,Minqi Chen,Wenyu Li,Xulin Wang,Jinjian Fu,Xiaohua Ye
DOI: https://doi.org/10.1016/j.vaccine.2021.01.056
IF: 4.169
2021-03-01
Vaccine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p><em>Streptococcus pneumoniae</em> (<em>S. pneumoniae</em>) is an important pathogen causing both invasive and non-invasive infections in children, with significant morbidity and mortality worldwide. This study aimed to determine the potential relationships between age and vaccine coverage and between multiple phenotype-genotype characteristics of <em>S. pneumoniae</em> isolated from children.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>All <em>S. pneumoniae</em> isolates were tested for antimicrobial susceptibility, virulence genes, serotypes, and sequence types. The restricted cubic spline models were used to reveal potential relationships between children age and pneumococcal vaccine coverage.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>For capsular-based vaccines, we observed a high coverage rate of 13-valent pneumococcal conjugate vaccine (PCV13, 85.8%) and a significantly non-linear relationship between children age and vaccine coverage (including PCV7, PCV10, and PCV13), with marked fluctuations in children aged &lt; 2 years. For protein-based and pilus-based vaccine candidates, we demonstrated dynamic non-linear relationships between age and vaccine coverage, maintaining a stable and high coverage rate of <em>ply</em> and <em>lytA</em> for all age groups. Moreover, there were significantly high-dimensional corresponding relationships among multiple phenotype-genotype characteristics of <em>S. pneumoniae</em> isolates (such as ST271 associated with serotype 19F, PI-2, and extensively drug-resistance).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Our findings suggest that the age for high PCV coverage being children aged ≥ 2 years and also provide important evidence for supporting <em>ply</em> and <em>lytA</em> as priority candidate targets for the development of new-generation protein vaccines.</p>
immunology,medicine, research & experimental
What problem does this paper attempt to address?